抄録
1) The effect of 4 weeks administration with immunomodulator PSK (Krestin) on the lipoprotein lipids contents in serum, was investigated in 10 patients with hyperlipidemia including three FH heterozygous patients. There was a significant decrease of T-cholesterol, β-lipoprotein in serum. HDL-cho, and triglyceride showed no significant alterations.
2) In a series of in vitro experiments, the effects of PSK on the LDL receptor activity of normal and FH heterozygous fibroblasts were investigated. In normal subject, PSK increased the uptake of 125I-LDL by+31% at 100μg/ml, while in FH heterozygous cells, the uptake was increased by +117% at 10μg/ml.
3) One of the reasons why β-lipoprotein in serum is decreased in patients of hyperlipidemia by PSK administration is considered to be that PSK enhanced the LDL receptor activity of fibroblasts. It was also suggested that PSK has stimulated more effectively LDL receptor activity of fibroblasts from hyperlipidemia patients than from normal subject.
